Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 26 MAY 2022

CSPC Pharmaceutical Group Limited (the "**Company**") is pleased to announce the poll results in respect of the resolutions proposed at the annual general meeting (the "**AGM**") of the Company held on 26 May 2022 as follows:

	ODDINA DV DESOL UTIONS	Number of Votes (%)		
	ORDINARY RESOLUTIONS	For	Against	
1.	To receive and consider the audited financial statements, the report of the directors and the independent auditor's report for the year ended 31 December 2021.9,098,696,936 (99.77%)21,035,300 (0.23%)As more than 50% of the votes were cast in favour of this ordinary resolution, the resolution was duly passed.			
2.	To declare a final dividend of HK10 cents per share for the year ended 31 December 2021. As more than 50% of the votes were cast in favour of this ordin passed.	9,108,962,038 (99.88%) nary resolution, the r	10,770,198 (0.12%) resolution was duly	

		Number of Votes (%)			
	ORDINARY RESOLUTIONS	For	Against		
3.	(a)(i) To re-elect Mr. WANG Zhenguo as an executive director.	8,744,799,200 (95.90%)	373,433,036 (4.10%)		
	As more than 50% of the votes were cast in favour of this ordinary resolution, the resolution was duly passed.				
	(a)(ii) To re-elect Mr. WANG Huaiyu as an executive director.	8,759,076,486 (96.06%)	359,155,750 (3.94%)		
	As more than 50% of the votes were cast in favour of this ordinary resolution, the resolution was duly passed.				
	(a)(iii) To re-elect Mr. CHAK Kin Man as an executive director.	8,643,371,972 (94.79%)	474,860,264 (5.21%)		
	As more than 50% of the votes were cast in favour of this ordinary resolution, the resolution was duly passed.				
	a)(iv) To re-elect Mr. WANG Bo as an independent non-executive director.	5,743,536,367 (62.99%)	3,374,695,869 (37.01%)		
	As more than 50% of the votes were cast in favour of this ordinary resolution, the resolution was duly passed.				
	(a)(v) To re-elect Mr. CHEN Chuan as an independent non-executive director.	6,024,469,509 (66.07%)	3,093,762,727 (33.93%)		
	As more than 50% of the votes were cast in favour of this ordinary resolution, the resolution was duly passed.				
	(b) To authorize the board of directors to fix the remuneration of directors.	9,106,017,665 (99.85%)	13,666,571 (0.15%)		
	As more than 50% of the votes were cast in favour of this ordinary resolution, the resolution was duly passed.				
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditor and to authorise the board of directors to fix the remuneration of auditor.	5,573,937,123 (61.12%)	3,545,795,113 (38.88%)		
	As more than 50% of the votes were cast in favour of this ordinary resolution, the resolution was duly passed.				

	ODDINA DV DESOL UTIONS	Number of Votes (%)			
	ORDINARY RESOLUTIONS	For	Against		
5.	To give a general mandate to the Directors to buy-back shares of the Company (ordinary resolution in item No.5 of the Notice of Annual General Meeting).	9,103,932,918 (99.83%)	15,799,318 (0.17%)		
	As more than 50% of the votes were cast in favour of this ordinary resolution, the resolution was duly passed as an ordinary resolution.				
6.	To give a general mandate to the Directors to issue new shares of the Company (ordinary resolution in item No.6 of the Notice of Annual General Meeting).	9,030,770,429 (99.02%)	88,961,807 (0.98%)		
	As more than 50% of the votes were cast in favour of this ordinary resolution, the resolution was duly passed as an ordinary resolution.				
7.	To grant a mandate to the Directors to grant options under the Share Option Scheme of the Company (ordinary resolution in item No.7 of the Notice of Annual General Meeting).	4,875,774,231 (53.46%)	4,243,910,005 (46.54%)		
	As more than 50% of the votes were cast in favour of this ordinary resolution, the resolution was duly passed as an ordinary resolution.				

As at the date of the AGM, the total number of issued and fully paid up shares of the Company was 11,933,219,732 shares. In relation to all resolutions proposed at the AGM, the total number of shares entitling the holders to attend and vote for or against the resolutions at the AGM was 11,933,219,732 shares. There were no shares entitling the holders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and no holder of shares was required to abstain from voting at the AGM under the Listing Rules.

Tricor Secretaries Limited, the Share Registrar of the Company, acted as scrutineer for the poll at the AGM.

The AGM was chaired by Mr. CAI Dongchen, the Chairman of the Board. All directors of the Company (except for Mr. PAN Weidong, Mr. WANG Huaiyu and Dr. LI Chunlei who were unable to attend due to other business commitments) attended the AGM in person or by electronic means.

Shareholders may refer to the circular dated 22 April 2022 for details of the above resolutions proposed at the AGM. The circular may be viewed and downloaded from the Company's website at <u>www.irasia.com/listco/</u><u>hk/cspc</u> or the designated website of The Hong Kong Exchanges and Clearing Limited at <u>www.hkexnews.hk</u>.

By order of the board CSPC Pharmaceutical Group Limited CAI Dongchen Chairman

Hong Kong, 26 May 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. PAN Weidong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.